{"disease":{"id":"metastatic-bladder-urothelial-carcinoma","name":"metastatic bladder urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05092958","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06129084","title":"A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Bernie Eigl","has_results":false},{"nct_id":"NCT04579224","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06138561","title":"Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT00365157","title":"Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02567409","title":"Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04200963","title":"A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT06764095","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03237780","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07087860","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06630416","title":"Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03513952","title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04940299","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02437370","title":"Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT02178241","title":"Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04963153","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03047213","title":"Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03582475","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT03715985","title":"Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT04848519","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04953104","title":"ARID1A and/or KDM6A Mutation and CXCL13 Expression","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05296564","title":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":3,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT05052372","title":"Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03935347","title":"Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}